Meet the Team
Co-Founder & Director
Damien Hancox is an experienced entrepreneur who specialises in identifying opportunities in emerging trends and builds businesses around the opportunities they represent. He started his career at a young age in the telecoms sector before moving into international retail development. Between 2001-2006 he built and sold a multi-million pound telecoms business. He has also successfully introduced brands to emerging markets and fast tracked their exposure for his customers and partners. He specialises in logistics and management, and bringing his experience of emerging markets together with that of imminent developments.
Professor Dennis F. Kinane
Medical and Scientific Advisor
Professor Kinane has been in academia and research for 35 years, directing research centres, schools and institutes at 5 Universities, in Europe and the USA. Currently, he is Professor of Immunology at the University of Geneva and on the board of several US, Chinese, Taiwanese and UK companies specialising in Health Care provision. In addition, he is Medical Director, Science Director and Compliance Officer for several companies (UK, Taiwanese and Korean) specialising in the Health and Diagnostic Sector. Professor Kinane Is also CEO of his own pharma start-up TheraJect which specializes in slow release anti-inflammatories. Through interest and commitment, he positions himself at the interface of human scientific research and business, hoping to bring the latest medical innovations to fruition. Recently he has been using his skills and experience to bring together business, health, government and higher education to address the COVID pandemic, by co-founding the charity, Project-Little-Boats. He continues to publish academic research as well as editing and reviewing grants and papers and performing due diligence on medical products.
Aziz serves as Executive Chairman of SpectrumX, having been an early stage cornerstone investor. After 14 years with Goldman Sachs, as Managing Director, Emerging Markets, Aziz recently left to join SpectrumX where he will focus on investor relations, governance and will formulate the company’s ESG policy. Aziz’s other interests include early stage Biotech, Carbon and Digital Assets. Additionally, Aziz runs his own mentorship programme, MaxPotential, to promote racial, gender and socio economic diversity in finance.
Ben Hibbert is a Project Director of nearly two decades, he holds a BSc in Quantity Surveying from the University of Salford and is also a Chartered Surveyor with many years of experience delivering complex schemes around the UK. Having led projects with values up to £250m in a range of sectors including Education, Manufacturing, Logistics, Research, Health and Retail, Ben has fine-tuned the art of taking a project from inception to delivery, and believes that strong relationships and managing communication between all parties sit at the heart of successful implementation.
Earl of Shrewsbury & Talbot
Charles Shrewsbury is a businessman and an active elected hereditary member of the House of Lords where his interests include Commerce and Industry, Agriculture and Rural issues. A former Director and Deputy Chairman of a major Building Society and a Past President of the Building Societies Association, he has also served as an NED on a number of Boards. He is Senior Advisor to DWF Law Plc, the largest LSE quoted legal services business. He acts in an advisory role for a number of major and medium sized businesses, both quoted and private. As he has for many years, he continues to promote British commerce and manufacturing industry both at home and abroad. He acts as an advisor to a number of high net worth individuals. Over 10 years from 1995, he purchased and assembled Cauldon Low Quarries, a major limestone quarry in North Staffordshire, selling to the Crown Estate in 2005. He is executive President of the Association of Manufacturers of Power Systems (AMPS).
Gordon Buchanan is a Consultant Surgeon, specialising in Colorectal and General surgery, with particular interests in minimally invasive cancer surgery, hernias as well as proctological disorders. Gordon began studying medicine at St Thomas’ Hospital, London over 30 years ago and has been in Consultant practice for almost 15 years. His MSc and MD research at St Mark’s Hospital, awarded by Imperial College and University of London assessed many areas of Complex anorectal fistula – he gained several prizes to visit other centres in USA (Lahey, Mayo and Cleveland clinics) and Hong Kong and undertook training fellowships at St Mark’s Hospital, Mount Sinai in Toronto as well as Laparoscopic Colorectal fellowships in UK. He has lectured internationally as well as operated by live link to train surgeons in Europe in Coloproctology. He regularly trains and teaches through the Royal College of Surgeons, Imperial College and on other invited courses. He has sat on the Council of both Association of Coloproctology of Great Britain and Ireland and Royal Society of Medicine Section of Coloproctology, where he is currently Vice President. Gordon has published over 50 peer reviewed papers, helped run and contributed to multicentre clinical trials as well as contributing to books, national guidelines and examining MD theses. Gordon has continued to work throughout the pandemic across the NHS and private sectors, and is an advocate for minimally invasive techniques, particularly in methods that hasten wound healing and minimise infection.
Derek is a highly professional and entrepreneurial international executive with extensive experience of commercial management, sales and marketing, supply chain and bringing complex products to market. He has over 33-years global pharmaceutical corporate experience and has worked with some of the largest companies in the world, most recently as Hospital Director for Accord UK Ltd, the biggest speciality company in the UK where he launched a number of generic, branded and biosimilar products. Derek brings a wealth of expertise in launching products across Europe and developing new structures, supply chain solutions and partner agreements to expedite uptake of new entrant products.
Dr Alexander Nill
Alexander Nill is an experienced investment banker and a serial entrepreneur. Over the last 27 years, he has been involved as an investor in more than 60 transactions, many of them of international scope. He was a shareholder in Toptier software which sold to SAP, he was an early shareholder in Shazam and was directly or indirectly involved in 16 IPO’s on the Deutsche Neue Markt Börse. He is a Co-Founder and board member of Sparta AG (a Hamburg based public corporate finance and investment company) and a Co-Founder and Chairman of the Board of IQ Capital AG (a Frankfurt based venture capital firm with offices in San Francisco, Zurich, Singapore, and London). He is taking an active approach managing the investment portfolio of his companies, Dr. Nill serves on several boards of directors. He is a director of IQ Finance plc (a financial services company) and is currently Chairman of f Athena Invest Gmbh. He is the co-owner of OTTO Stadtlander GmbH the leading commodity trader for long and extra long staple Cotton and has further interest in precious metal trading.